Table 1.
Study | Model | Data source | Development | Validation | Sample size | Population | Average age | Outcome | Readmission (%) | ||
Dev | Val | Dev | Val | ||||||||
Moretti et al57 | EuroHeart PCI score | Hospital database | NA | Ext | – | 1192 | ACS | 71 (7) | 30d | 4.7 | |
Asche et al46 | NR | Retrospective cohort | Yes | Split | 2446 | 612 | AMI | 65 (15) | 30d | 8.9 | |
Cediel et al58 | TARRACO Risk score | Retrospective cohort | Yes | No | 611 | 401 | AMI type 2, ischaemia | D: 78 (17) V: 60 (21) |
30d | 2.6 | |
Retrospective cohort | Yes | No | 611 | 401 | AMI type 2, ischaemia | D: 78 (17) V: 60 (21) |
180d | 7.9 | |||
Chotechuang et al36 | GRACE | Retrospective cohort | NA | Ext | – | 152 | AMI | 60.5 (6.3) | 30d | 5.3 | |
GRACE | Retrospective cohort | NA | Ext | – | 152 | AMI | 60.5 (6.3) | 180d | 9.2 | ||
Hilbert et al59 | AMI decision tree | Registry | Yes | Ext | 10 848 | 10 701 | AMI | NR | 30d | 20.6 | 19.7 |
Dodson et al18 | SILVER-AMI 30-day readmission calculator | Prospective cohort | Yes | Split | 2004 | 1002 | AMI | 81.5 (5.0) | 30d | 18.2 | |
Kini et al60 | NR | Registry | Yes | Split | 60 742 | 26 107 | AMI | 76.5 (8.0) | 90d | 27.5 | |
Nguyen et al19 | AMI READMITS score | Retrospective cohort | Yes | Split | 661 | 165 | AMI | 65.5 (12.8) | 30d | 13 | |
Full-stay AMI model | Retrospective cohort | Yes | Split | 661 | 165 | AMI | 65.5 (12.8) | 30d | 13 | ||
CMS AMI administrative model | Retrospective cohort | NA | Ext | – | 826 | AMI | 65.5 (12.8) | 30d | 13 | ||
Krumholz et al20 | CMS AMI administrative model | Registry | Yes | Split, Ext | 100 465 | 321 088 | AMI | 78.7 (8.0) | 30d | 18.9 | 20.0 (Ext) NR (split) |
CMS AMI medical model | Registry | Yes | Split | 130 944 | 130 944 | AMI | 76.2 (7.3) | 30d | 20 | ||
Rana et al33 | Elixhauser index | Hospital database | NA | Ext | – | 1660 | AMI | 67.9 | 30d | 6.3 | |
HOSPITAL score | Hospital database | NA | Ext | – | 1660 | AMI | 67.9 | 30d | 6.3 | ||
Atzema et al47 | AFTER Part 2 scoring system | Retrospective cohort | Yes | Split | 2343 | 1167 | Arrhythmia, AF | D: 68.6 (14.7) V: 68.3 (15.1) |
30d | 7 | 7.6 |
Lahewala et al40 | CHADS2 | Administrative | NA | Ext | – | 116 450 | Arrhythmia, AF | <75 | 30d | 15.8 | |
CHADS2 | Administrative | NA | Ext | – | 116 450 | Arrhythmia, AF | <75 | 90d | 25.1 | ||
CHA2DS-VASc | Administrative | NA | Ext | – | 116 450 | Arrhythmia, AF | 65–74 | 30d | 15.8 | ||
CHA2DS-VASc | Administrative | NA | Ext | – | 116 450 | Arrhythmia, AF | 65–74 | 90d | 25.1 | ||
Benuzillo et al61 | CRSS | Hospital database | Yes | Boot, Ext | 2589 | 896 (Ext) 500 (Boot) |
CABG | 66.7 (9.9) | 30d | 9.1 | 8.2 (Ext) 9.1 (Boot) |
Deo et al62 | 30-day CABG readmission calculator | Administrative | Yes | Boot | 155 054 | 1000 | CABG | 65.4 (10.4) | 30d | 12.5 | |
Engoren et al55 | NR | Hospital database | Yes | Split | 2644 | 2711 | CABG | NR | 30d | 7.6 | 8 |
Lancey et al63 | NR | Registry | Yes | Split | 2341 | 2520 | CABG | 64.5 (10.5) | 30d | 8.8 | 9.5 |
Rosenblum et al41 | The STS PROM score | Hospital database | NA | Ext | – | 21 719 | CABG | 63.5 (10.7) | 30d | 9.3 | |
Zitser-Gurevich et al64 | NR | Prospective cohort | Yes | Split | 2266.5 | 2266.5 | CABG | 65–74 | 30d | 13.3 | |
NR | Prospective cohort | Yes | Split | 2266.5 | 2266.5 | CABG | 65–74 | 100d | 24.1 | ||
Zywot et al42 | CABG risk scale | Administrative | Yes | Ext | 126 519 | 94 318 | CABG | D: 70–74 V: 70–74 |
30d | 23 | 21 |
Ahmad et al21 | CMS HF administrative model | Prospective cohort | NA | Ext | – | 183 | HF | 61 (18) | 30d | 22.4 | |
Amarasingham et al22 | ADHERE | Hospital database | NA | Ext | – | 1372 | HF | 56.5 | 30d | 24.1 | |
CMS HF administrative model | Hospital database | NA | Ext | – | 1372 | HF | 56.5 | 30d | 24.1 | ||
Tabak mortality score | Hospital database | NA | Ext | – | 1372 | HF | 56.5 | 30d | 24.1 | ||
Au et al23 | Administrative claims model: HF 30-day mortality | Administrative | NA | Ext | 59 652 | 59 652 | HF | 75.8 (12.7) | 30d | 15.9 | |
Charlson Comorbidity Score | Administrative | NA | Ext | 59 652 | 59 652 | HF | 75.8 (12.7) | 30d | 15.9 | ||
CMS HF administrative model | Administrative | NA | Ext | 59 652 | 59 652 | HF | 75.8 (12.7) | 30d | 15.9 | ||
LACE | Administrative | NA | Ext | 59 652 | 59 652 | HF | 75.8 (12.7) | 30d | 15.9 | ||
Bardhan et al65 | NR | Hospital database | Yes | No | 40 983 | – | HF | 69.2 (15.7) | 30d | 7 | |
Betihavas et al66 | NR | RCT secondary analysis | Yes | Boot | 280 | 200 | HF | 74 (64–81) | 28d | 18 | |
Cox et al24 | CMS HF administrative model | Hospital database | No | Ext | – | 1454 | HF | 75 (12) | 30d | 21.5 | |
CMS HF medical model | Hospital database | No | Ext | – | 1454 | HF | 75 (12) | 30d | 21.5 | ||
Delgado et al67 | 15-day CV readmission risk score | Prospective cohort | Yes | Boot | 1831 | 500 | HF | 72.4 (12.1) | 15d | 7.1 | |
30-day CV readmission risk score | Prospective cohort | Yes | Boot | 1831 | 500 | HF | 72.4 (12.1) | 30d | 13.9 | ||
Formiga et al30 | CMS HF medical model | Hospital database | NA | Ext | – | 719 | HF | 78.1 (9) | 30d | 7.6 | |
CMS HF medical model | Hospital database | NA | Ext | – | 719 | HF | 78.1 (9) | 90d | 14.4 | ||
Frizzell et al25 | CMS HF administrative model | Registry | NA | External | – | 56 477 | HF | 80 (2) | 30d | 21.2 | |
Hammill et al26 | CMS HF administrative model | Registry | NA | Ext | – | 24 163 | HF | 81 | 30d | 21.9 | |
Hilbert et al59 | HF decision tree | Registry | Yes | Ext | 39 682 | 38 409 | HF | NR | 30d | 25.5 | 25.2 |
Hummel et al31 | CMS HF medical model | Prospective cohort | NA | Ext | – | 1807 | HF | 79.8 (7.6) | 30d | 27 | |
Huynh et al48 | NR | Prospective cohort | Yes | Ext | 430 | 1046 | HF | D: 75 (19) V: 67 (17) |
30d | 21 | 24 |
NR | Prospective cohort | Yes | Ext | 430 | 1046 | HF | D: 75 (19) V: 67 (17) |
90d | 43 | 42 | |
Ibrahim et al34 | HOSPITAL score | Retrospective cohort | NA | Ext | – | 692 | HfpEF | 68.3 (11.8) | 30d | 27.3 | |
LACE/LACE+ index | Retrospective cohort | NA | Ext | – | 692 | HfpEF | 68.3 (11.8) | 30d | 27.3 | ||
Keenan et al27 | CMS HF administrative model | Registry | Yes | Split, Ext. | 28 319 | 845 291 | HF | 79.9 (7.8) | 30d | 23.6 | 23.7 (Ext) NR (Split) |
CMS HF medical model | Registry | Yes | Split, Ext. | 64 329 | 64 329 | HF | 75–84 | 30d | 23.7 | ||
Kitamura et al53 | FIM | Retrospective cohort | NA | Ext | – | 113 | HF | 80.5 (6.7) | 90d | 20.4 | |
Leong et al68 | 30-day HF readmission risk score | Retrospective cohort | Yes | Split | 888 | 587 | HF | D: 70.0 (12.7) V: 69.1 (12.8) |
30d | 9.9 | |
Li et al49 | NR | Retrospective cohort | Yes | Split | 51 783 | 25 887 | HF | D: 84 (12) V: 84 (11) |
30d | 24.2 | |
Lim et al69 | NR | Registry | Yes | No | 4566 | – | HF | 70.5 (12.0) | 30d | 6.6 (car) 13 (all) | |
Reed et al28 | AH model | Administrative | Yes | Split | NR | NR | HF | NR | 30d | NR | |
CMS HF administrative model | Administrative | NA | Split | – | NR | HF | NR | 30d | NR | ||
Hasan | Administrative | NA | Split | – | NR | HF | NR | 30d | NR | ||
LACE | Administrative | NA | Split | – | NR | HF | NR | 30d | NR | ||
PARR-30 | Administrative | NA | Split | – | NR | HF | NR | 30d | NR | ||
Salah et al70 | ELAN-HF score | Prospective cohort secondary analysis | Yes | No | 1301 | – | HF | 74 (16) | 180d | 36.1 | |
Sudhakar et al32 | CMS HF medical model | Hospital database | NA | Ext | – | 1046 | HF | 65.2 (16.6) | 30d | 35.3 | |
Tan et al71 | NR | Hospital database | Yes | Split | 246 | 104 | HF | D: 67.7 (12.3) V: 69.0 (12.9) |
90d | 24.5 | 11.7 |
Wang et al72 | NR | Hospital database | Yes | No | 4548 | – | HF | 68.5 (27.6) | 30d | 25.1 | |
Wang et al38 | LACE | Retrospective cohort | NA | Ext | – | 253 | HF | 56.6 (11.5) | 30d | 24.5 | |
Yazdan-Ashoori et al29 | CMS HF administrative model | Prospective cohort | NA | Ext | – | 378 | HF | 73.1 (13.1) | 30d | 26 | |
LACE | Prospective cohort | NA | Ext | – | 378 | HF | 73.1 (13.1) | 30d | 26 | ||
Disdier Moulder et al73 | NR | Prospective cohort | Yes | No | 258 | HF, ACS, NR | 70.5 (23) | 30d | 17 | ||
NR | Prospective cohort | Yes | No | 258 | HF, ACS, NR | 70.5 (23) | 180d | 38 | |||
Raposeiras-Roubín et al37 | GRACE | Retrospective cohort | NA | Ext | – | 4229 | HF, ACS | 68.2 (18.7) | 30d | 2.6 | |
Burke et al35 | HOSPITAL score | Retrospective cohort | NA | Ext | – | HF: 3189 AMI: 767 |
HF, AMI | 65.8 (16.8) | 30d | HF: 18.2 AMI: 17.4 | |
Minges et al74 | NR | Registry | Yes | Split | 193 899 | 194 179 | HF, PCI | 65+ | 30d | 11.4 | |
Pack et al75 | NR | Administrative | Yes | Split | 30 826 | 7706 | HVD | 64.9 (12.2) | 90d | 12.8 | |
Oliver-McNeil et al76 | ICD readmission-risk score | Registry | Update | Ext | 182 | – | ICD | 69 (11) | 30d | 17.6 | |
Wasfy et al52 | Pre-PCI model | Registry | Yes | Split | 24 052 | 12 008 | NR | 64.8 (12.5) | 30d | 10.4 | |
Barnett et al77 | NR | Registry | Update | Ext | 19 964 | 19 964 | Surgical | 65.3 (12.4) | 30d | 11.4 | |
Brown et al43 | STS augmented clinical model | Prospective cohort | Update | Boot | 1046 | NR | Surgical | 65.4 (9.8) | 30d | NR | |
STS 30-day readmission model | Prospective cohort | NA | Ext | – | 1194 | Surgical | 73.3 (10.1) | 30d | NR | ||
Espinoza et al78 | 30-day readmission score after cardiac surgery | Retrospective cohort | Yes | Split | 2529 | 2567 | Surgical | 65.1 (11.5) | 30d | 11.9 | |
Ferraris et al54 | READMIT | Prospective cohort | Yes | 2574 | Surgical | 63 (11) | 30d | 9.8 | |||
Kilic et al79 | NR | Retrospective cohort | Yes | Split | 3898 | 1295 | Surgical | D:61.9 (14.7) V: 61.6 (15.1) |
30d | 10 | 11 |
Stuebe et al80 | NR | Hospital database | Yes | No | 4800 | Surgical | 60–69 | 30d | 12 | ||
Tam et al44 | NR | Retrospective cohort | Yes | Boot | 63 336 | NR | Surgical | 66.2 (10.7) | 30d | 11.3 | |
Khera et al45 | TAVR 30-Day readmission risk model | Administrative | Yes | Boots, Ext | 39 305 | 40 (Boot) 885 (Ext) | TAVR | D: 81.3 V: 81.7 |
30d | 16.2 | 16.2 (Boot) 18.9 (Ext) |
Sanchez et al50 | NR | Registry | Yes | Split | 6903 | 3442 | TAVR | D: 81.1 (7.9) V: 81.3 (7.9) |
30d | 9.8 | 10.7 |
Age is reported as mean (SD); median (IQR) or average age as reported in the study.
ACS, acute coronary syndrome; ADHERE, Acute Decompensated Heart Failure Registry; AF, atrial fibrillation; AH, Adventist Health Off-the-shelf model; AMI, acute myocardial infarction; Boot, bootstrapping; CABG, coronary artery bypass grafting; Car, cardiac-related; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category; CMS, Centers for Medicare and Medicaid Services; CRSS, CABG Readmission Risk Score; d, days; Dev, development; ELAN-HF, European Collaboration on Acute Decompensated Heart Failure; Ext, external validation; FIM, motor and cognitive Functional Independence Measure; GRACE, Global Registration of Acute Coronary Events; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HVD, heart valve disease; ICD, implantable cardioverter defibrillator; LACE, Length of stay, acuity of the Admission, Comorbidity of the patient and Emergency department use in the duration of 6 months before admission; NA, not applicable; NR, not reported; PARR-30, Patients at Risk of Re-admission within 30 days; PCI, percutaneous coronary intervention; READMITS, Renal Function, Elevated Brain Natriuretic Peptide, Age, Diabetes Mellitus, Nonmale Sex, Intervention with Timely Percutaneous Coronary Intervention, and Low Systolic Blood Pressure; SILVER-AMI, Comprehensive Evaluation of Risk Factors in Older Patients with AMI; Split, random split; STS PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TARRACO, Troponin Assessment for Risk stRatification of patients without Acute COronary atherothrombosis; TAVR, transcatheter aortic valve replacement; Val, validation.